JP2023526567A - バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法 - Google Patents

バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法 Download PDF

Info

Publication number
JP2023526567A
JP2023526567A JP2023513266A JP2023513266A JP2023526567A JP 2023526567 A JP2023526567 A JP 2023526567A JP 2023513266 A JP2023513266 A JP 2023513266A JP 2023513266 A JP2023513266 A JP 2023513266A JP 2023526567 A JP2023526567 A JP 2023526567A
Authority
JP
Japan
Prior art keywords
patient
compound
groups
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526567A5 (enExample
Inventor
デボラ ファーガソン
ダブリュ． クリスチャン ウィグリー
コリン メイヤー
ジェイ． ウォーレン ハフ
ロバート エム． ジュニア クラル
Original Assignee
リアタ ファーマシューティカルズ ホールディングス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リアタ ファーマシューティカルズ ホールディングス リミテッド ライアビリティ カンパニー filed Critical リアタ ファーマシューティカルズ ホールディングス リミテッド ライアビリティ カンパニー
Publication of JP2023526567A publication Critical patent/JP2023526567A/ja
Publication of JP2023526567A5 publication Critical patent/JP2023526567A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023513266A 2020-05-09 2021-05-07 バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法 Pending JP2023526567A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063022479P 2020-05-09 2020-05-09
US63/022,479 2020-05-09
US202063053056P 2020-07-17 2020-07-17
US63/053,056 2020-07-17
PCT/US2021/031282 WO2021231208A1 (en) 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078603A Division JP2026129953A (ja) 2020-05-09 2026-05-08 バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法

Publications (2)

Publication Number Publication Date
JP2023526567A true JP2023526567A (ja) 2023-06-21
JP2023526567A5 JP2023526567A5 (enExample) 2024-05-16

Family

ID=76197607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513266A Pending JP2023526567A (ja) 2020-05-09 2021-05-07 バルドキソロンメチルまたはそのアナログを用いてｃｏｖｉｄ－１９を処置する方法

Country Status (11)

Country Link
US (1) US20230255982A1 (enExample)
EP (1) EP4146226A1 (enExample)
JP (1) JP2023526567A (enExample)
KR (1) KR20230022164A (enExample)
CN (1) CN115803059B (enExample)
AU (1) AU2021273460A1 (enExample)
BR (1) BR112022022599A2 (enExample)
CA (1) CA3177913A1 (enExample)
IL (1) IL298008A (enExample)
MX (1) MX2022014034A (enExample)
WO (1) WO2021231208A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL285832B2 (en) * 2013-08-23 2024-01-01 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
CA3240963A1 (en) * 2021-12-23 2023-06-29 Steven Laplante Drug combinations for inhibiting coronavirus replication
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN118903154B (zh) * 2024-08-22 2025-11-11 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 化合物CDDO-Im用于预防或治疗口蹄疫的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528300A (ja) * 2013-08-23 2016-09-15 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
DK1465615T3 (da) 2002-01-15 2012-11-12 Dartmouth College Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
EP2094651A1 (en) 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
JP5570415B2 (ja) 2007-05-08 2014-08-13 アボット・ラボラトリーズ 他のペプチド型に対する交差反応性の低いヒトｂ型ナトリウム利尿ペプチドアッセイ
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
KR100905466B1 (ko) 2007-10-08 2009-07-02 한국과학기술원 차세대 셀룰라 통신시스템에서의 중계 통신방법
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
SG173601A1 (en) 2009-02-13 2011-09-29 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me
AU2011240690C1 (en) * 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
BR112019009256A2 (pt) * 2016-11-08 2019-07-16 Reata Pharmaceuticals, Inc. métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
WO2021202547A1 (en) * 2020-04-01 2021-10-07 Triterpenoid Therapeutics, Inc. Methods and compositions for treating and preventing viral infection
WO2021202245A1 (en) * 2020-04-02 2021-10-07 Egaceutical Corporation Viral treatment regimens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528300A (ja) * 2013-08-23 2016-09-15 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMMUNITY, vol. 44, JPN6025053682, 2016, pages 1379 - 1391, ISSN: 0005769039 *
JOURNAL OF VETERINARY MEDICAL SCIENCE, JPN6025053681, 5 August 2020 (2020-08-05), ISSN: 0005769040 *
MED ARCH., vol. 74(2), JPN6025016734, April 2020 (2020-04-01), pages 134 - 138, ISSN: 0005582598 *

Also Published As

Publication number Publication date
CN115803059B (zh) 2026-05-01
WO2021231208A1 (en) 2021-11-18
EP4146226A1 (en) 2023-03-15
CN115803059A (zh) 2023-03-14
IL298008A (en) 2023-01-01
CA3177913A1 (en) 2021-11-18
MX2022014034A (es) 2023-01-11
US20230255982A1 (en) 2023-08-17
AU2021273460A1 (en) 2022-12-08
BR112022022599A2 (pt) 2023-03-21
KR20230022164A (ko) 2023-02-14

Similar Documents

Publication Publication Date Title
JP6633812B2 (ja) バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
JP6701407B2 (ja) バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
JP6894923B2 (ja) 胆汁うっ滞性及び線維性の疾患の処置方法
CN115803059B (zh) 使用甲基巴多索隆或其类似物治疗covid-19的方法
JP6557684B2 (ja) 線維性疾患の治療に用いられるｐｐａｒ化合物
EP2854811A1 (en) Use of amg 900 for the treatment of cancer
CN114072205A (zh) 用tie-2激活剂治疗高血压的方法
HK40089696A (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof
WO2026085128A1 (en) Method of treating liver diseases or disorders with ask1 inhibitors
HK40052300A (en) Methods of treating and preventing a renal disease using bardoxolone methyl or analogs thereof
HK40011743B (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
EA042085B1 (ru) Способ лечения и предотвращения заболевания почек

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260626